Jonathan R. Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Curtis Building, Suite 611A
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2
  2. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
  3. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis from the International Phase III ESPAC-3 Clinical Trial
  4. Complex HuR function in pancreatic cancer cells
  5. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  6. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
  7. CRISPR knockout of the HuR gene causes a xenograft lethal phenotype
  8. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
  9. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
  10. Therapeutic implications of molecular subtyping for pancreatic cancer
  11. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
  12. DNA repair, overview
  13. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment
  14. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
  15. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
  16. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR
  17. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
  18. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
  19. Delivery of Therapeutics Targeting the mRNA Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
  20. The landscape of pancreatic cancer therapeutic resistance mechanisms